Home > Neurology > Risk of MS relapse high when natalizumab is stopped for pregnancy

Risk of MS relapse high when natalizumab is stopped for pregnancy


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Network Open
Reuters Health - 24/01/2022 - For women with multiple sclerosis (MS) on natalizumab, there is a high risk of relapse and related disability when the drug is stopped for pregnancy, according to data from the German Multiple Sclerosis and Pregnancy Registry.  Women with MS "need to be informed about the risks of early natalizumab cessation due to pregnancy or planned pregnancy, and treatment alternatives should be considered," write Dr. Kerstin Hellwig of Ruhr University Bochum and colleagues in JAMA Network Open.  The magnitude of risk for relapse when natalizumab is stopped for pregnancy is unclear.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on